- FDA Inspections Back Up To Speed (Except Those Now Deemed Unnecessary) August 16, 2022
- Landmark Drug Pricing Bill Set to Become Law; HP&M Releases Summary Slide Deck August 15, 2022
- New Lawsuit Challenges FDA’s Authority to Compel Patent Certifications August 11, 2022
- Second Circuit Agrees that Copay Assistance Programs May Violate the Anti-Kickback Statute August 5, 2022
- ACI’s Paragraph IV Disputes Master Symposium – September 21-22, 2022 (Chicago) August 5, 2022
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized
Crossing the Line: Kickbacks Come Under Increased Government Scrutiny
April 9, 2007During the past several years, government enforcement authorities have focused an increasing amount of attention on the marketing activities of medical device companies. This increased scrutiny has taken the form of investigations through subpoenas and intervention in qui tam lawsuits (lawsuits initiated by a third party on behalf of the government). Often, these actions are brought by whistleblowers under the Federal False Claims Act (FCA).
Michelle L. Butler and Jeffrey N. Wasserstein recently published an article in Medical Device & Diagnostic Industry addressing kickback issues in the medical device industry.
Categories: Medical Devices
Search FDA Law Blog
Subscribe
Latest Tweets
Tweets by @fdalawblogAwards & Honors
- The Best
Lawyers in America
US News & World Report - Ranked in Chambers USA 2018
- FDA Inspections Back Up To Speed (Except Those Now Deemed Unnecessary) August 16, 2022
- Landmark Drug Pricing Bill Set to Become Law; HP&M Releases Summary Slide Deck August 15, 2022
- New Lawsuit Challenges FDA’s Authority to Compel Patent Certifications August 11, 2022
- Second Circuit Agrees that Copay Assistance Programs May Violate the Anti-Kickback Statute August 5, 2022
- ACI’s Paragraph IV Disputes Master Symposium – September 21-22, 2022 (Chicago) August 5, 2022
- Big Molecule Watch Blog
- Bloomberg BNA Health Care Blog
- Drug and Device Law Blog
- Eye on FDA
- FDA Matters
- Harvard Law Bill of Health
- IN VIVO Blog
- Internet Drug News.com
- Lachman Consultants Blog
- Medical Devices Today
- Orange Book Blog
- The Orange Book Insights Blog
- Pharma IQ
- Pharmalot
- SCOTUS Blog
- The Volokh Conspiracy
- WLF Legal Pulse
- Advertising and Promotion (Federal Trade Commission)
- Advertising and Promotion (OPDP)
- Animal Drugs and Feeds
- Biosimilars
- Cannabis
- cGMP Compliance
- Consumer Product Safety Commission
- Controlled Substances
- Cosmetics
- COVID19
- Current Affairs
- Dietary Supplements
- Drug Development
- Drug Enforcement Administration
- Enforcement
- FDA News
- Foods
- Foods and Dietary Supplements
- Fraud and Abuse
- Government Pricing
- Hatch-Waxman
- Health Care
- Health Privacy
- Import/Export
- In Vitro Diagnostic Devices
- Jobs
- Medical Devices
- Miscellaneous
- Orphan Drugs
- OTC Drugs and Cosmetics
- Prescription Drugs and Biologics
- Product Jurisdiction and Combination Products
- Reimbursement
- Tissue Products
- Tobacco
- Uncategorized